Report Code: A12067 | Nov 2023 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Paget’s Disease Treatment Market
Request Now !A Paget’s disease, also known as Osteitis deformans, is a chronic bone disorder, which affects a single bone (monostotic) or multiple bones (poly-ostotic) resulting in abnormally long, weak, and brittle bone structure. Disorganized bone production or excessive bone breakdown are the major causes of the disease that may result in pain and fractures in joints around the damaged bone. The remolding of bone is disrupted in Paget's disease, resulting in brittle and thick bone. Most commonly involved bones include the femur, pelvis, spine, tibia, and skull .In addition, other medical problems associated with this disease include arthritis, kidney stones, nervous system issues, and vision loss. Majority of people with Paget's disease are asymptomatic, but some patients experience symptoms such bone pain, secondary osteoarthritis, bone deformities, excessive warmth, and neurologic problems.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected witness a significant growth in the future owing to the demand for vaccine and treatment
drugs for COVID-19. This, in turn, is expected to have a significant impact on the Paget’s disease treatment market.
Top Impacting Factors
Increase in prevalence of Paget’s disease among people across the world and surge in geriatric population are some factors that boost the market growth.
In addition, rise in awareness about health and government initiatives to improve healthcare infrastructure contribute toward the market growth. Moreover, increase in research and activities by key players to identify viral and genetic causes of Paget’s disease is expected to propel the market growth.
Furthermore, the approval of new and highly effective drugs for the treatment of the disease is projected to increase the uptake of drugs by patients and ultimately boost the market growth. Rise in number of cases related to arthritis and bone injuries is further fueling the market growth.
However, patent expiry of drugs such as Fosamax, Miacalcin, and Reclast is likely to hamper the growth of paget’s disease treatment market.
Market Trends
New Product Launches to Flourish the Market
In March 2020, EA Pharma Co., Ltd. and its parent company Eisai Co., Ltd. launched the MHLW (Ministry of Health, Labour and Welfare) approved “Actonel 17.5 mg tablets” for treatment of Paget’s disease of bone.
In May 2021, Leucadia Pharmaceuticals Inc. launched its latest FDA-approved generic, Calcitonin Salmon Injection, USP, Synthetic. The injection is therapeutically equivalent to MIACALCIN and it is used to treat osteoporosis in postmenopausal women and to treat Paget's disease. It is indicated for the early treatment of hypercalcemic emergencies when a rapid decrease in serum calcium is required.
Key Benefits of the Report
Questions Answered in the Paget’s Disease Treatment Market Report
Paget’s disease Treatment Market Report Highlights
Aspects | Details |
---|---|
By Type |
|
By Route of Administration |
|
By End User |
|
By Region |
|
Key Market Players | Sun Pharmaceutical Industries Ltd., Fresenius Kabi, Neopharma Inc., Teva Pharmaceutical Industries Ltd., Merck KGaA, Allergan, Mylan NV, Sanofi S.A.,, Mallinckrodt Pharmaceuticals, Novartis AG |
Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers